Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk

Journal of Clinical Pathology

Volumn 64, Issue 9, 2011, Pages 829-831

  Stebbing, Justin ^a   Thiyagarajan, Arun ^a   Surendrakumar, Veena ^a   Payne, Rachel ^a   Krell, Jonathan ^a   Szydlo, Richard ^a   Peston, David ^a   Lewis, Jacqueline S ^a   Coombes, R Charles ^a   Shousha, Sami ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; LAPATINIB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL PROLIFERATION; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80051887158     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2011.089433     Document Type: Article

References (18)

1. Gutierrez M.C., Detre S., Johnston S., et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogenactivated protein kinase. J Clin Oncol 2005;23:2469-2476 (Pubitemid 47050837)
2. Osborne C.K., Shou J., Massarweh S., et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11(2 Pt 2):865-70s.
3. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-935 (Pubitemid 38868139)
4. Schiff R., Massarweh S.A., Shou J., et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10(1 Pt 2):331-36S
5. Bartlett J.M., Ellis I.O., Dowsett M., et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 2007;25:4423-4430 (Pubitemid 350013848)
6. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139 (Pubitemid 38637993)
7. Gazdar A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009;361:1018-1020
8. Polychronis A., Sinnett H.D., Hadjiminas D., et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005;6:383-391 (Pubitemid 40753744)
9. Rimawi M.F., Shetty P.B., Weiss H.L., et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010;116:1234-1242
10. Van den Broek L.J., Van de Vijver M.J. Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. Appl Immunohistochem Mol Morphol 2000;8:316-321
11. Burness M.L., Grushko T.A., Olopade O.I. Epidermal growth factor receptor in triplenegative and basal-like breast cancer: Promising clinical target or only a marker? Cancer J 2010;16:23-32.
12. Walker R.A., Bartlett J.M., Dowsett M., et al. HER2 testing in the UK: Further update to recommendations. J Clin Pathol 2008;61:818-824 (Pubitemid 351969725)
13. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810 (Pubitemid 46211358)
14. Goldstein N.S., Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 2001;92:1331-1346
15. Finn R.S., Gagnon R., Di Leo A., et al. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol 2009;27:5552-5558
16. Finn R.S., Press M.F., Dering J., et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009;27:3908-3915
17. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137 (Pubitemid 33674041)
18. Mueller K.L., Yang Z.Q., Haddad R., et al. EGFR/Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal 2010;5:8.